Characterisation of Antifungal Prophylaxis and Therapy Among Inpatients With Haematological Malignancies in Non‐Research Clinical Setting: A Multicentre Italian Experience
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND: Invasive fungal infections (IFI) are a prominent cause of morbidity and mortality among patients with haematological malignancies (HMs). Diagnostic work-up excluding IFI is mandatory in case of persistent fever while antifungal treatment (AFT) is started. OBJECTIVES: We aimed to describe antifungal prophylaxis (AFP) and AFT among haematological patients with IFI managed in clinical practice, focusing on microbiological and radiological characteristics, 30-day outcome and therapeutic options after AFT failure. PATIENTS AND METHODS: We enrolled 461 consecutive adult and paediatric patients with HMs, in which an intravenous AFT was started from September 2019 to December 2021. After serum galactomannan (GM) and chest CT scan, they were stratified as presenting with proven, probable, and possible IFI according to 2008 EORTC-MSG criteria. Fungal isolates were detected from culture tests in 17.5% and from biopsy in 1.5% of patients. Mould active and non-active AFP was used in 42.3% and 16.5% of cases, respectively. RESULTS: Use of AFP significantly impact on serum GM negativity (p < 0.001 for mould active and p = 0.04 for mould non active, respectively). Use of mould non-active prophylaxis significantly correlates with radiological imaging (typical p = 0.0037, IC (0.370-0.825) and negative -p = 0.0031, IC (0.241-0.750)). Toxicity, progression, and drug interaction were responsible for therapy change in 58 (12%) patients: 18 patients with proven/probable IFI needed multiple courses of AFT. At 30 days from starting AFT, overall mortality with IFI was 23/461 (5%). CONCLUSIONS: In this observational study, we recorded an impact of AFP on serum GM results and radiological imaging. Need of AFT should be carefully evaluated, as diagnostic work-up might be affected not only by specific disease risk but also by previous AFP.
Source: Mycoses
DOI: 10.1111/myc.70150
Authors: Criscuolo Marianna, Bonanni Matteo, Martino Giordana, Farina Francesca, Verga Luisa, Marchesi Francesco, Basilico Claudia, Del Principe Maria Ilaria, Tisi Maria Chiara, Cattaneo Chiara, Picardi Marco, Bonuomo Valentina, Fracchiolla Nicola, Candoni Anna, Perruccio Katia, Stanzani Marta, Cesaro Simone, Fanci Rosa, Dargenio Michela, Forghieri Fabio, Ballanti Stelvio, Cudillo Laura, Cuccaro Annarosa, Carraro Francesca, Zama Daniele, Armiento Daniele, Garzia Maria Grazia, Spolzino Angelica, Busca Alessandro, Pagano Livio
Institutions: Agostino Gemelli University Polyclinic, Istituti di Ricovero e Cura a Carattere Scientifico, Università Cattolica del Sacro Cuore, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Sapienza University of Rome, IRCCS Ospedale San Raffaele, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele, Instituto Nazionale Tumori Regina Elena, Ospedale di Circolo e Fondazione Macchi, Aziende Socio Sanitarie Territoriale dei Sette Laghi, University of Rome Tor Vergata, Ospedale San Bortolo, Azienda ULSS 8 Berica, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, Federico II University Hospital, University of Naples Federico II, University of Verona, University of Turin, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Azienda Ospedaliera di Perugia, Ca' Foncello Hospital, Azienda Ospedaliera Universitaria Integrata Verona, Azienda Ospedaliero-Universitaria Careggi, University of Florence, Azienda Ospedaliera San Giovanni Addolorata, Ospedale Regina Margherita, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, Università Campus Bio-Medico, Campus Bio Medico University Hospital, Azienda Ospedaliera San Camillo-Forlanini, University of Parma, Istituto Oncologico Veneto, Ospedale di Parma, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,780
Funder: Gilead Sciences
OpenAlex ID: W7119725239
